Tencent Holdings has received regulatory approval to import Nvidia's advanced H200 AI chips, a significant move that enhances its competitive edge in cloud and AI services while navigating ongoing US technology restrictions.
Netflix's bold, all-cash offer to acquire Warner Bros. Discovery for an estimated $72-83 billion is testing investor confidence and regulatory boundaries. The proposed mega-deal, which would dramatically reshape the streaming landscape, faces intense scrutiny over antitrust concerns and the strain it could place on Netflix's historically disciplined balance sheet.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
A Wall Street Journal report reveals a major investment by UAE's Sheikh Tahnoon bin Zayed Al Nahyan in a Trump-linked cryptocurrency company days before the 2024 inauguration, followed by a reversal of U.S. policy on advanced AI chip exports to the UAE.
Cboe Global Markets is exploring a revival of simplified, event-based binary options for retail investors, aiming to compete with surging prediction markets while navigating a complex regulatory landscape.
After months of political gridlock and a series of no-confidence votes, France's parliament is poised to adopt the contentious 2026 budget. The survival of Prime Minister Sebastien Lecornu's government hinges on Monday's vote, marking a critical juncture for the nation's fiscal and political stability.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
After a period of Bitcoin dominance, a confluence of technological maturity, shifting institutional narratives, and regulatory clarity could propel Ethereum back into the spotlight. Analysts point to its foundational role in decentralized finance and a series of upcoming catalysts as reasons for a potential breakout year.
Zions Bancorporation has authorized a new $75 million stock repurchase program, a move analysts see as a bet on its undervalued shares and a commitment to shareholder returns as regional banks navigate a cautious regulatory environment.
Google has agreed to a $135 million settlement to resolve a class-action lawsuit alleging unauthorized data collection by its Android operating system, pending court approval. The deal also mandates clearer user controls and disclosures.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
A British Columbia court has given its final approval to Coeur Mining's planned acquisition of New Gold, moving the deal that will create a North American precious metals giant one step closer to its expected H1 2026 closing.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
Coeur Mining's acquisition of New Gold has received final court approval in British Columbia, marking a pivotal step toward creating a larger, diversified precious metals producer. The deal is poised to reshape the competitive landscape for mid-tier gold and silver miners in North America.
The U.S. Office of the Comptroller of the Currency has granted Nubank conditional approval to establish a national bank, a significant step that could see the digital banking leader offer federally regulated crypto custody alongside traditional banking products in the United States.
Analyses from multiple artificial intelligence models project divergent paths for Ethereum, Solana, and XRP by 2026, highlighting varying risk-reward profiles based on technological adoption, regulatory landscapes, and market structure.
Shares in Alligator Energy (ASX:AGE) jumped sharply after the company announced key progress at its Samphire uranium project in South Australia, including the launch of a field recovery trial and advancing mining lease approvals, setting the stage for a bankable feasibility study targeted for early 2027.
